efalizumab


Also found in: Wikipedia.

efalizumab

a rarely used immunosuppressant.
indications This drug is used in adults 18 years of age and older to treat moderate to severe plaque psoriasis.

efalizumab

A recombinant, humanized monoclonal antibody to CD11 a used to treat moderate to severe PSORIASIS.
References in periodicals archive ?
6,10) More recently, biologic agents have been implicated in SSLR, including rituximab, efalizumab, and infliximab.
001) Dermatology revealed study which studied efficacy of efalizumab in patients with moderate-to-severe psoriasis after 16 weeks of treatment patients with PASI 75 were 71% compared to PGA 0, 1 showing 62% showing that PASI show better improvement than PGA.
Favourable responses to photochemotheray with or without acitretin, etretinate, photodynamic therapy and efalizumab have been reported but further studies are called for regarding these therapies.
Ng noted that a trial of efalizumab (Raptiva) had terminated because of an increased risk for progressive multifocal leukoencephalopathy.
Clinical improvement of pityriasis rubra pilaris with efalizumab in a pediatric patient.
Refractory Subacute Cutaneous Lupus Erythematosus With a Response to Efalizumab.
More recently, PML has been reported in patients being treated with immunosuppressive drugs, including efalizumab (withdrawn from the market), infliximab, mycophenolate mofetil, rituximab, and most notably, natalizumab.
Infliximab, efalizumab, tocilizumab and rituximab have been studied in this regard, but no firm recommendations can be provided at this stage.
Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.
Efalizumab is a recombinant humanised monoclonal IgG1 antibody that binds to CD11a, a subunit of leukocyte function-associated antigen 1 (LFA-1) (24).